By SquaredTown on October 23, 2025
SAN DIEGO, Oct. 23, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced that Orion has obtained an exclusive focused commercial license to one of Abzena's monoclonal antibodies (mAbs) that targets a cancer of high...